trial
as of 2026-07-0120110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
NCTId NCT01568229
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Terminated
Enrollment
111 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-05
Primary completion
2013-06
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Drugs
Indications
Sponsors
AmgenLead Sponsor
Sites
44 total
Little Rock, United StatesSpringdale, United StatesLong Beach, United StatesOakland, United StatesOrange, United StatesHialeah, United StatesKissimmee, United StatesAtlanta, United StatesRockville, United StatesFlowood, United StatesPrinceton, United StatesBuffalo, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
111
Phase
PHASE2
Primary Completion Date
2013-06
Status
TERMINATED
relationships
The graph out of here